Clear Intended Use
Define what the AI is for, who uses it, where it acts and where its authority ends.
Healthcare & Life Sciences · Medical AI Governance
Govern Medical AI With Clear Evidence, Human Oversight and Release Decisions
DataConsultant helps healthcare and life-sciences organisations establish practical governance for AI used across clinical, diagnostic, research, safety and operational workflows. We connect intended use, data provenance and quality, evaluation evidence, human oversight, privacy, security, supplier assurance, release decisions and production monitoring so accountable leaders can decide when an AI system is ready to use—and when it is not.
Risk-based controls tied to intended use and consequence
Clinical, scientific, data and technical evidence connected
Human accountability, escalation and release authority defined
Monitoring, change and retirement governed across the lifecycle
Scope, timeline and commercial terms are confirmed after reviewing your AI portfolio, intended uses, clinical or scientific risk, jurisdictions, evidence, data flows, supplier dependencies and operating model.
Medical AI Governance Decision MapFrom intended use to controlled operation
Lifecycle governed
Traceable Evidence
Connect datasets, model versions, evaluation results, limitations and acceptance criteria.
Human Accountability
Make review, override, escalation, release and residual-risk ownership explicit.
Lifecycle Control
Govern monitoring, incidents, supplier changes, model updates and retirement.
1
Why Medical AI Governance Breaks Down in Real Healthcare and Life-Sciences Workflows
The problem is rarely a missing policy alone. It is the gap between a policy and the evidence, decision rights and operational controls needed to govern a specific AI system that touches patient care, research, safety, quality or regulated product activity.
Current StateFragmented, project-by-project assurance
- Demo-led AI decisions
- Unclear risk appetite
- Separate clinical and technical reviews
- Inconsistent evidence packages
- Unowned supplier changes
- Monitoring defined after release
Target StateRisk-based, evidence-led governance
- Use-case-specific criteria
- Accountable decision rights
- Repeatable evaluation evidence
- Documented release gates
- Supplier and change controls
- Continuous monitoring and incidents
Assess Where Medical AI Decisions Currently Depend on Informal Evidence
Review inventory coverage, intended-use clarity, evaluation evidence, human oversight, release authority, supplier dependencies and monitoring gaps across priority AI systems.
Service Definition
A Controlled Decision System Around Medical AI—not a Policy Binder
DataConsultant designs medical AI governance as a connected operating capability. The framework links the AI system’s intended use to the clinical or scientific workflow, affected people, data provenance, evaluation questions, failure consequences, control evidence, human oversight, approval authority and post-release signals. This allows governance to be proportionate: more consequential uses receive deeper evidence and tighter controls, while lower-risk uses can follow a lighter but still accountable pathway.
Portfolio-level governanceInventory, taxonomy, risk tiers, ownership, standards and decision forums.
System-level assuranceIntended use, evidence, controls, release criteria, residual risk and monitoring.
Workflow-level oversightHuman review, override, escalation, documentation and operational fallback.
Lifecycle-level controlVersioning, change impact, supplier updates, incidents, revalidation and retirement.
2
What Our Medical AI Governance Service Covers Across the Lifecycle
The service can be scoped around one high-priority AI system, a portfolio of systems or an enterprise governance model. The lifecycle connects use-case intake with evidence, release and ongoing operation rather than treating approval as a one-time event.
Intended UsePurpose, users, population, workflow, benefit and boundaries.
AI InventoryInternal, embedded, vendor, pilot and production systems.
Risk TieringConsequence, autonomy, exposure, sensitivity and regulatory context.
Data AssessmentProvenance, quality, labels, representativeness and transformations.
EvaluationPerformance, safety, robustness, subgroups and use-case acceptance.
Human OversightReview, confirmation, override, escalation and fallback.
Release DecisionApprove, restrict, remediate or stop with accountable ownership.
Operate & ChangeMonitoring, incidents, model updates, re-evaluation and retirement.
Governance depth is not one-size-fits-all. The evidence and control burden should reflect the AI system’s intended use, affected workflow, decision consequence, autonomy, data sensitivity, regulatory status, model behaviour and supplier dependency.
3
Medical AI Governance Starts With the Real Data and Decision Chain
A clinically or scientifically meaningful AI control cannot be designed without understanding where data comes from, how it is transformed, what the model produces, which human action follows and how downstream outcomes are observed.
Patient / ParticipantIdentity, consent, demographics, history and context.
Encounter / StudyClinical encounter, diagnostic event, protocol or research activity.
Clinical / Research EvidenceImaging, labs, notes, biomarkers, outcomes and observations.
Governed AI DatasetCurated inputs, labels, transformations, metadata and version.
Model / AI SystemModel, prompt, retrieval, rules, tool use and dependencies.
AI OutputScore, classification, recommendation, generated text or prioritisation.
Human Decision / ActionReview, confirmation, override, escalation and clinical or research action.
Outcome / MonitoringPerformance, safety, workflow, incidents, drift and feedback.
4
Medical AI Governance Capability Map
Trusted medical AI requires clinical and scientific fit, trustworthy data, evidence, accountable human decisions and operational controls to work as one connected capability.
Clinical / Scientific FitIntended use, population, workflow, benefit and limitations.
Data Quality & ProvenanceOrigin, labels, missingness, representativeness and versioning.
Safety & RobustnessFailure modes, stress conditions, resilience and fallback.
Fairness & Subgroup EvidenceRelevant population slices, variation and equitable performance.
Privacy & SecurityMinimisation, access, sensitive data, attack surface and leakage.
Human OversightReview, confirmation, override, escalation and stop-use authority.
Evidence & TraceabilityEvaluation records, lineage, model cards and decision evidence.
Governance & Decision RightsAccountable owners, forums, thresholds, exceptions and residual risk.
Supplier / Model AssuranceThird-party evidence, dependencies, change notices and exit risk.
Operational MonitoringPerformance, drift, incidents, model change and retirement.
5
Reference Control Architecture for Medical AI
The architecture must connect source-system context to governed data, model dependencies, the clinical or research application and the human workflow. The categories below are illustrative and should be adapted to the client estate; they do not assume a specific vendor stack.
Healthcare & Research Sources
- EHR / EMR
- PACS / RIS
- LIS / pathology
- CTMS / eCOA
- Safety systems
- Research repositories / devices
Integration & Processing
- APIs and interfaces
- Batch / streaming
- Transformation logic
- Terminology mapping
- De-identification
- Feature preparation
Governed Data Layer
- Curated datasets
- Dataset versions
- Metadata / lineage
- Quality rules
- Access controls
- Retention / consent context
Model / AI Layer
- ML / predictive models
- Foundation models
- RAG / retrieval
- Prompts / instructions
- Embeddings / tools
- Model registry / versions
Clinical / Research Application
- Decision support
- Diagnostic workflow
- Research workflow
- Safety operations
- Documentation support
- Alerts / prioritisation
Human Decision & Monitoring
- Review and confirmation
- Override / escalation
- Outcome capture
- Performance signals
- Incident response
- Change / retirement
Identity & access
Privacy & minimisation
Metadata & lineage
Quality & validation
Version & change control
Audit & evidence retention
For generative AI, the governed system boundary may include the base model, retrieval index, prompt templates, guardrails, tool permissions, external services and model-provider changes—not only the model endpoint.
6
Governance Questions Change With the Medical AI Use Case
A useful governance framework starts with how AI participates in a real decision. The same metric or review checklist cannot be assumed to work across imaging, prediction, generative documentation, clinical research and safety operations.
Diagnostic / Imaging Decision Support
AI may prioritise studies, detect findings or support interpretation. Governance needs to reflect modality, clinical population, reader workflow, failure consequence and downstream action.
Key question: What false-negative, false-positive and subgroup performance evidence is decision-relevant?
Deterioration / Risk Prediction
Scores may influence monitoring, escalation or treatment attention. Controls should address timeliness, missingness, population shift, calibration and how clinicians respond to alerts.
Key question: Does the score improve the intended decision without creating unsafe alert burden or blind spots?
Clinical Documentation or GenAI Copilot
Generated text can accelerate documentation or synthesis but may introduce unsupported statements, omissions, source errors or sensitive-data leakage.
Key question: What must the clinician verify, what sources are visible, and what errors trigger stop-use or redesign?
Clinical Trial Eligibility & Recruitment
AI may identify potentially eligible participants from complex records. Governance should connect protocol criteria, source-data quality, missed-candidate risk and human confirmation.
Key question: Are criteria interpreted consistently across sites and patient groups, with traceable evidence for review?
Pharmacovigilance or Safety Triage
AI can support case intake, classification or prioritisation. Controls should distinguish automation convenience from decisions that influence safety review and reporting.
Key question: Can reviewers reconstruct why a case was prioritised, suppressed or escalated?
Research Evidence Extraction & Synthesis
AI may structure or summarise literature, real-world evidence or trial documents. Provenance, source coverage, extraction accuracy and citation traceability become core controls.
Key question: Can a reviewer trace material claims back to the source and detect missing or misrepresented evidence?
Map One Priority Medical AI Use Case From Data Source to Release Evidence
Connect intended use, datasets, evaluation questions, human workflow, release criteria and monitoring signals before scaling governance across the portfolio.
7
Control Domains for Safe, Responsible and Traceable Medical AI
Controls should be explicit enough to support a release decision and practical enough to operate. DataConsultant helps translate governance principles into evidence requirements, accountable owners, thresholds, exceptions and monitoring actions.
Intended Use & System Boundaries
- Purpose, users and population
- Workflow entry and exit points
- Supported and prohibited uses
- Dependencies and fallback
- Material assumptions and limitations
Data Governance & Quality
- Dataset provenance and version
- Completeness and coding consistency
- Label / ground-truth quality
- Representativeness and subgroup coverage
- Transformation and feature traceability
Evaluation & Acceptance
- Use-case-specific evaluation questions
- Failure-mode and subgroup testing
- Robustness and stress conditions
- Acceptance thresholds and rationale
- Limitations and residual risk
Human Oversight & Human Factors
- Human confirmation requirements
- Interpretability needed by the user
- Override and escalation authority
- Training and workflow readiness
- Stop-use and fallback criteria
Privacy & Security
- Data minimisation and access
- Sensitive-data exposure
- Prompt / output leakage risk
- Adversarial and misuse scenarios
- Logging, retention and incident links
Supplier & Third-Party AI
- Evidence and documentation review
- Model / service dependency mapping
- Change-notification expectations
- Security and data-use terms
- Continuity and exit planning
Release, Exceptions & Residual Risk
- Decision authority by risk tier
- Mandatory evidence package
- Exceptions and compensating controls
- Residual-risk acceptance
- Conditions and restricted release
Monitoring, Change & Retirement
- Performance and data signals
- Incident severity and escalation
- Drift and workflow impact
- Model / prompt / retrieval changes
- Revalidation, rollback and retirement
8
Regulatory and Standards Context: Apply It System by System
Medical AI does not have one universal regulatory status. Obligations depend on intended use, product classification, jurisdiction, role in the clinical or research workflow and other facts. The governance model should therefore capture regulatory applicability as evidence—not assume every AI system follows the same path.
How to Use External Requirements Without Turning Governance Into a Checklist
For India, medical-device assessment may involve the Medical Devices Rules, 2017 and current CDSCO medical-device software guidance where the software falls within the applicable medical-device framework. In the United States, FDA digital-health guidance differentiates use cases and includes current guidance on clinical decision support, AI-enabled device software and lifecycle change. In the European Union, the AI Act uses a risk-based framework; Article 6 and product-law interactions matter when determining whether a system is high-risk. Application dates are phased, so timing should be checked at the point of decision.
Map the exact intended use firstRegulatory analysis is unreliable when the AI purpose, user, population, decision role and product boundary are vague.
Separate legal applicability from internal riskAn AI use can be operationally or clinically material even when it is not classified the same way as a regulated medical-device function.
Keep evidence reusable across regimesProvenance, evaluation, human oversight, change control, incident records and accountability are valuable even when jurisdiction-specific documentation differs.
Track changing obligationsRegulatory status, guidance, supplier functionality and product-law relationships can change. Governance should have an owner for reassessment.
Important: DataConsultant provides governance, data, AI and transformation consulting. This page is not legal, medical or regulatory advice and does not represent certification, conformity assessment or a guarantee of regulatory approval.
CDSCO — Medical Device & DiagnosticsIndia-facing medical-device information and current guidance, including medical-device software resources.
CDSCO — Medical Devices Rules, 2017Official rules source for medical devices in India; applicability should be assessed for the intended use and product context.
FDA — Guidances with Digital Health ContentCurrent FDA digital-health guidance index, including clinical decision support, AI-enabled device software and cybersecurity topics.
FDA — AI-Enabled Device Software FunctionsFDA draft guidance covering lifecycle management and marketing-submission considerations for AI-enabled device software functions.
European Commission — AI ActOfficial implementation overview for the EU AI Act, including phased application dates and high-risk requirements.
WHO — Regulatory Considerations on AI for HealthWHO guidance on regulatory considerations for artificial intelligence used in health.
NIST — AI Risk Management Framework 1.0Voluntary AI risk-management framework that can inform governance structure and risk treatment.
ISO/IEC 42001:2023Artificial intelligence management-system standard; useful as a governance reference where relevant to organisational objectives.
9
How DataConsultant Builds the Medical AI Governance Capability
The engagement moves from business and clinical context to evidence-based governance design, then into mobilisation. Activities are adapted to the maturity of the organisation and the materiality of the systems in scope.
Stage 1FrameAgree business objectives, sponsors, decisions, scope and risk appetite.
Stage 2InventoryIdentify AI systems, owners, workflows, suppliers, jurisdictions and lifecycle state.
Stage 3AssessReview intended use, data, evidence, controls, roles and current gaps.
Stage 4DesignDefine governance tiers, decision rights, templates, gates and operating model.
Stage 5ValidateApply the model to priority use cases and test evidence and decision workflows.
Stage 6MobilisePrioritise remediation, assign owners, configure governance forums and backlog.
Stage 7OperationaliseEmbed release, monitoring, incident, supplier and change processes.
10
Medical AI Governance Maturity Assessment — Illustrative Structure
A maturity view can make gaps visible across governance dimensions. The table and radar below illustrate the assessment structure only; they are not client results, benchmark claims or pre-scored ratings.
| Dimension | Ad hoc | Defined | Repeatable | Controlled | Scaled |
|---|---|---|---|---|---|
| AI inventory & ownership | |||||
| Intended-use clarity | |||||
| Risk classification & materiality | |||||
| Data provenance & quality | |||||
| Clinical / scientific evaluation | |||||
| Subgroup & fairness evidence | |||||
| Human oversight | |||||
| Supplier assurance | |||||
| Release & change control | |||||
| Monitoring, incidents & retirement |
Illustrative Target Profile
Visual example only — not a client score
11
Business Objective → Medical AI Evidence Mapping
Illustrative example: an AI-assisted radiology prioritisation workflow. The value of governance is the traceable chain from the clinical objective to evidence, release authority and post-release monitoring.
ObjectiveImprove prioritisationHelp urgent studies receive appropriate attention without displacing safe workflow controls.
Intended UsePrioritise worklistDefined modality, setting, users, population and non-diagnostic boundary.
Failure ConsequenceUnsafe delay or overloadMissed urgent case, excessive false alerts or inappropriate reliance.
Evaluation QuestionUseful and safe?Performance, subgroup behaviour, workflow impact and failure conditions.
EvidenceTraceable evaluationDataset provenance, metrics, error analysis, subgroup results and human factors.
AcceptanceDefined thresholdsApproved criteria, known limitations, escalation and release conditions.
ReleaseAccountable decisionApprove, restrict, remediate or stop with residual risk recorded.
MonitoringOperational signalsPerformance, case mix, alert burden, incidents, drift and change triggers.
12
Tangible Deliverables From a Medical AI Governance Engagement
Outputs are selected to support real governance decisions and implementation. The final deliverable set depends on whether the engagement focuses on one priority system, an AI portfolio or an enterprise operating model.
DELIVERABLE 01
Medical AI Governance Framework
Principles, scope, roles, risk tiers, decision forums, control domains and lifecycle requirements.
DELIVERABLE 02
AI Inventory & Classification Model
Inventory fields, ownership, use-case taxonomy, lifecycle state, materiality and routing logic.
DELIVERABLE 03
Intended-Use & Boundary Template
Purpose, users, populations, inputs, outputs, workflow role, prohibited uses and dependencies.
DELIVERABLE 04
Risk & Control Matrix
Failure modes, risk drivers, required evidence, accountable controls, exceptions and residual risk.
DELIVERABLE 05
Medical AI Data Requirements
Provenance, quality, representativeness, labels, lineage, versioning and monitoring requirements.
DELIVERABLE 06
Evaluation & Acceptance Blueprint
Evaluation questions, test scenarios, metrics, subgroup evidence, thresholds and limitations.
DELIVERABLE 07
Human Oversight & Decision Rights
Review, confirmation, override, escalation, release, stop-use and residual-risk ownership.
DELIVERABLE 08
Third-Party AI Assurance Pack
Supplier evidence requests, dependency map, change expectations, monitoring and exit considerations.
DELIVERABLE 09
Release, Change & Monitoring Workflow
Approval gates, evidence package, change triggers, incident handling, revalidation and retirement.
DELIVERABLE 10
Implementation & Enablement Roadmap
Prioritised workstreams, owners, dependencies, governance mobilisation and capability-transfer actions.
13
From Governance Design to Working Release and Monitoring Controls
Implementation should sequence the most material decisions first. A practical roadmap usually combines governance mobilisation, portfolio baseline, priority-system remediation, evidence tooling and operating-process adoption.
Mobilise Governance
Confirm sponsors, forums, decision rights, policy scope, risk appetite and accountable owners.
Baseline the AI Estate
Build or reconcile inventory, intended uses, suppliers, workflows, jurisdictions and lifecycle state.
Prioritise Material Systems
Use risk tiering to identify AI systems needing deeper evidence, remediation or restricted use.
Embed Evidence & Gates
Operationalise templates, evaluation packages, approval paths, exceptions and release decisions.
Activate Monitoring
Define signals, thresholds, incident handling, supplier changes, revalidation and rollback decisions.
Scale & Transfer
Integrate governance into portfolio intake, delivery, procurement, quality and internal capability.
Timeline: confirmed after scoping. It depends on the number and materiality of AI systems, stakeholder access, evidence availability, jurisdictions, architecture complexity, supplier dependencies and implementation depth.
Turn the Governance Framework Into Working Release and Monitoring Controls
Move from principles to owners, evidence templates, risk tiers, approval gates, supplier assurance, change control and operational monitoring that teams can actually use.
Client Inputs
What We Need From Your Team
Good governance design depends on evidence from the people who own the workflow, data, system, risk and operating decisions. Missing evidence is recorded as a limitation rather than filled with assumptions.
Initial enquiry safety: please do not place patient, participant, clinical-record, trial-subject or other confidential sensitive data in the website enquiry form. We can agree secure information-sharing arrangements during mobilisation.
14
How the Medical AI Governance Capability Can Be Sustained
Governance must continue after framework approval. DataConsultant can support the operating model through advisory, assurance, monitoring governance and capability transfer, with responsibilities agreed around the client’s existing clinical, quality, regulatory, data, security and technology teams.
15
Custom Scope & Pricing for Medical AI Governance
DataConsultant does not publish a fixed fee for this engagement because one-use-case assurance, portfolio governance design and enterprise implementation have materially different evidence, stakeholder and delivery requirements.
Request a Quote
Pricing and timeline are confirmed after discovery. We scope the decisions to be supported, systems and stakeholders in scope, evidence depth, jurisdictions, required deliverables and implementation responsibilities before proposing commercial terms.
Request Medical AI Governance PricingAI portfolio sizeNumber of systems, use cases, business units and lifecycle stages.
Risk & intended-use depthClinical consequence, autonomy, affected population and decision role.
Evidence availabilityData lineage, evaluation records, supplier documentation and current controls.
Jurisdictions & regulatory contextMarkets, product classifications and internal assurance obligations.
Data & architecture complexitySource systems, integrations, model dependencies and sensitive-data flows.
Stakeholder & workshop scopeClinical, research, quality, regulatory, privacy, security, data and technology participation.
Deliverable depthAssessment only, framework design, system-level evidence or full operating model.
Implementation & ongoing supportMobilisation, tooling, managed governance, training and operational assurance needs.
16
Is This the Right Engagement for Your Organisation?
Medical AI governance is most useful when the organisation needs a repeatable decision system around AI risk and evidence. Some needs are better handled first by a narrower technical, legal, clinical, security or regulatory specialist workstream.
Strong fit when you need to…
- Create an enterprise medical AI governance model across healthcare or life-sciences functions.
- Bring clinical, scientific, data, technology, risk and quality evidence into one release pathway.
- Assess a portfolio of AI systems and prioritise deeper assurance by materiality.
- Define human oversight, accountable release authority, exceptions and residual-risk ownership.
- Govern third-party, embedded or generative AI that existing procurement controls do not fully cover.
- Move from one-time approval to monitoring, incident, change and retirement governance.
You may need a different or additional specialist when…
- You require legal interpretation, formal legal opinion or jurisdiction-specific counsel.
- You require statutory certification, notified-body activity, regulator submission or formal conformity assessment.
- You need a medical diagnosis, clinical judgement or professional medical responsibility transferred to a consultant.
- You need penetration testing, specialist cybersecurity assessment or another narrow technical assurance activity only.
- You need a model built or a dataset labelled but do not need governance, evidence or release controls.
- You need formal clinical study design or biostatistical services outside the agreed data and AI governance scope.
Define the Governance Model Before Medical AI Scale Outpaces Accountability
Establish the inventory, risk tiers, evidence requirements, decision rights, release gates and monitoring model your teams need before AI adoption becomes harder to control.
18
Medical AI Governance FAQs
Questions enterprise buyers commonly need answered before scoping governance, assurance and implementation support.
What is medical AI governance?
Medical AI governance is the set of decision rights, evidence requirements, controls and lifecycle processes used to determine how AI can be designed, acquired, validated, released, monitored, changed and retired in healthcare and life-sciences settings. It connects intended use, clinical or scientific risk, data quality, model performance, human oversight, privacy, security, supplier assurance and operational monitoring.
What does DataConsultant’s Medical AI Governance service cover?
Scope can include AI inventory and ownership, intended-use definition, risk tiering, data and provenance requirements, evaluation design, acceptance criteria, subgroup and fairness evidence, human-oversight design, supplier assurance, release gates, change control, monitoring, incident governance, evidence templates, operating-model design and implementation planning. Final scope is agreed after discovery.
Which healthcare and life-sciences organisations can use this service?
The service can be relevant to healthcare providers, diagnostics and imaging organisations, medtech and digital-health businesses, pharmaceutical and biotechnology companies, clinical-research organisations and other regulated or safety-sensitive teams using AI in clinical, research, safety, quality or operational workflows.
Do all medical AI systems require the same controls?
No. Governance should be proportionate to the intended use, affected users, decision consequence, autonomy, data sensitivity, model behaviour, regulatory status, supplier dependency and operational context. A low-impact administrative assistant should not automatically inherit the same evidence burden as an AI function that can materially influence diagnosis, treatment, trial safety or another high-consequence decision.
How should clinical decision-support AI be governed?
Governance should begin with a precise intended use and user population, then define data requirements, failure modes, performance and subgroup evidence, human review, escalation and override expectations, release criteria, change controls and post-release monitoring. Regulatory classification and obligations must be assessed separately for the specific product, jurisdiction and intended use.
What additional controls are useful for generative AI in healthcare?
Generative AI often requires explicit controls for grounding and retrieval quality, hallucination and unsupported claims, source attribution, prompt and system-instruction management, sensitive-data leakage, tool permissions, human verification, model-provider changes, version traceability and monitoring of production interactions. The required controls depend on the workflow and consequence of error.
How does data quality fit into medical AI governance?
Data quality is part of the evidence chain. Useful controls can include provenance, completeness, coding consistency, label quality, missingness, representativeness, subgroup coverage, site or device variation, transformation traceability, dataset versioning and drift monitoring. The quality criteria should be linked to the intended use and the failure modes being managed.
Can the framework cover third-party or vendor AI?
Yes. Third-party AI can be governed through supplier due diligence, intended-use alignment, evidence review, data and privacy terms, security expectations, model and service dependencies, change-notification requirements, service monitoring, incident escalation and exit or substitution planning. Evidence availability and contractual leverage should be treated as explicit risks rather than assumed.
How are human oversight and decision rights defined?
The engagement can define who may use the system, what information they need to review, when human confirmation is mandatory, who can override or stop use, who accepts residual risk, and who owns release, monitoring, incidents and change decisions. These rights should reflect real workflow authority rather than a generic governance chart.
Does this service guarantee regulatory compliance or medical-device approval?
No. DataConsultant can help structure governance, evidence, controls and regulatory-readiness work, but the service does not replace legal advice, clinical responsibility, formal conformity assessment, notified-body activity, regulator submission, statutory audit or specialist product-certification work. Applicable obligations must be determined for the specific system, intended use and jurisdiction.
What deliverables can we expect?
Typical outputs can include a medical AI governance framework, AI inventory and classification model, intended-use template, risk and control matrix, data and evidence requirements, evaluation and acceptance blueprint, human-oversight model, supplier-assurance pack, release and change workflow, monitoring and incident model, operating model and implementation roadmap.
How long does a Medical AI Governance engagement take?
A reliable timeline is confirmed after scoping. Duration depends on the number and materiality of AI systems, business units and jurisdictions, stakeholder availability, evidence quality, workflow complexity, supplier dependencies, regulatory context, the depth of validation required and whether implementation support is included.
How is Medical AI Governance pricing determined?
DataConsultant uses custom scope and pricing for this service. Commercial scope is shaped by the AI portfolio, number of use cases and jurisdictions, assessment depth, clinical or scientific risk, data and architecture complexity, workshops, evidence review, required deliverables, implementation support and ongoing operating needs. A quote is provided after discovery.
Can DataConsultant help implement and operate the governance model?
Yes. Follow-on support can include governance mobilisation, inventory rollout, evaluation and evidence templates, release-gate implementation, data-quality and lineage controls, supplier assurance, monitoring and incident processes, operating-model support, delivery assurance, knowledge transfer and managed governance operations. Responsibilities and acceptance criteria are agreed before implementation.
Request a Medical AI Governance Consultation
Share a non-sensitive summary of your requirement. DataConsultant will use it to prepare the initial scoping discussion.